Abstract
BackgroundMurine chimeric antigen receptor T (CAR-T) cell therapy has demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, the potential immunogenicity of the murine single-chain...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have